Artiva Biotherapeutics to Present at TD Cowen Health Care Conference
Event summary
- Artiva Biotherapeutics will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 4, 2026, at 1:10 p.m. EST.
- Management will also hold investor meetings during the conference.
- Artiva's lead program, AlloNK® (AB-101), is in three ongoing clinical trials for B-cell driven autoimmune diseases.
- The company's pipeline includes CAR-NK candidates targeting solid and hematologic cancers.
The big picture
Artiva Biotherapeutics' participation in the TD Cowen Health Care Conference underscores its focus on engaging with investors and showcasing its clinical-stage cell therapies. The company's lead program, AlloNK®, is a key differentiator in the autoimmune disease space, while its CAR-NK pipeline targets a broader oncology market. The strategic partnership with GC Cell provides a technological edge, but the company's ability to translate this into commercial success will be closely watched.
What we're watching
- Clinical Progress
- How the ongoing clinical trials for AlloNK® will impact Artiva's strategic positioning in the autoimmune disease space.
- Investor Sentiment
- Whether the investor meetings will generate renewed interest or skepticism about Artiva's pipeline.
- Pipeline Expansion
- The pace at which Artiva advances its CAR-NK candidates for cancer treatment.
Related topics